Breast Cancer - Female
404
74
105
174
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
27 trials with published results (7%)
Research Maturity
174 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.5%
18 terminated out of 404 trials
90.6%
+4.1% vs benchmark
8%
33 trials in Phase 3/4
16%
27 of 174 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 174 completed trials
Clinical Trials (404)
Effects of Negative Pressure Wound Bandaging After Mastectomy
Exploring Breast Referral Behaviours in Primary Care
IORT-Breast at Medical Center Navicent Health
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
Physical Activity for Adults in the Ontario Breast Screening Program
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer
Quality of Life Improvement During Chemotherapy
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2
99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26
Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Safety, Feasibility, and Outcomes of Early Rehabilitation After Breast Cancer Surgery
Comparison Immune Response in Paravertebral and Erector Spinal Plane Block in Breast Cancer Patients
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC